Dadbrotheroftwins, I can't speak for Black-Ops but if I may share something shared to me by Tradinplaces a long time ago. I once shared with him my similar concern regarding potential competition in the marketplace for another investment in which we are long-term holders. I asked him whether or not he believed another viable competitor could possibly enter the market and what that might mean to our potential. To give a very brief background, we're talking about a unique cybersecurity product unlike anything yet seen in its ability. He reminded me that when Henry Ford put out the first automobile, it was unique and profitable. It served a global need and there weren't any real competitors at that point. Today, there are MANY effective competitors and yet Ford is still very profitable.
The gist of that story is that there's plenty of room for healthy competition. I would argue that there's no way that Leronlimab can meet the need of everyone who needs it right now for one simple reason and that's supply. If there's another drug, like Ivermectin that can help save lives, isn't that really more important? The financial rewards of being an investor in CYDY will, in my opinion, absolutely happen in time. There are far too many people who are suffering and/or dying who need help RIGHT now and something like Ivermectin can make a difference without compromising our potential profits. Also, remember what we've read on here that not every person will respond with 100% efficacy for any one particular drug and that will most likely include Leronlimab. Granted, a large percentage will most likely respond favorably if what little we know re: LL's efficacy holds true in the upcoming results.
In short, there's plenty of profit to be made. Number one concern, heal people and financial gains will naturally follow.
News 
Market Data 
Discover 
AI
